ATS 2024 Final Program

Click on the session title to view the speakers

245

TUESDAY • MAY 21

P686 Asthma-associated Non-classical Human Leukocyte Antigen Class II Proteins Are Expressed in Human Lung Antigen Presenting Cells P687 Innate Immune Biomarkers Associated With Acute Asthma Exacerbations P688 Unraveling the Role of the Neutrophil in a Mouse Model of Pollutant-aggravated Allergic Asthma

With Hematologic Malignancy or Prior Hematopoietic Cell Transplantati P1346 Immunization Advice in ATS Clinical Guidance Documents: A Systematic Review P1348 Mental Health and Long-COVID In Peru: A Qualitative Exploration

BEHAVIORAL • CLINICAL THEMATIC POSTER SESSION

BEHAVIORAL • CLINICAL THEMATIC POSTER SESSION

C37 HEALTH SERVICES RESEARCH IN PULMONARY HYPERTENSION 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P197 Practice Patterns for Screening and Treating Interstitial Lung Disease-related Pulmonary Hypertension at Specialty Care Centers in the United States P198 Real-World Medication Cost Burden Among Patients Treated for Pulmonary Arterial Hypertension P199 Trends in Medicare Spending on Medications for Pulmonary Hypertension, 2012-2021 P200 Impact of Delaying Access to Sotatercept on Patients Living With Pulmonary Arterial Hypertension P201 Expert Consensus on Best Practices for Oral Selexipag Titration and Management of Expected Side Effects in the Treatment of Pulmonary Arterial Hypertension (PAH) P202 Engaging With People With Lived Experience of Pulmonary Arterial Hypertension (PAH) Provides Impactful Insights Across the Clinical Development Pathway P203 A Cross Functional Collaboration to Achieve One Goal: The Pulmonary Arterial Hypertension (PAH) Experience San Diego Convention Center Area C (Hall A-B2, Ground Level)

C36 ADVANCES IN COVID-19, LUNG INFECTION, AND TUBERCULOSIS 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1339 Evaluation of the LTBI Care Cascade in an Academic Internal Medicine Practice and Referral TB Center: Sailing Through the Waves of a Pandemic P1340 Improving Outpatient Management of COVID-19 Through a Cloud-based Clinical Decision Supporting System P1341 Use of Alternative and Complementary Health Therapies One Year After Hospitalization for Severe COVID-19 P1342 The Impact of the COVID-19 Pandemic on the Research Productivity of K-awardees P1343 Evaluating a Canadian Crisis Standards of Care Policy During the COVID-19 Surge in New York City: A Simulated Observational Cohort Study P1344 A Quality Improvement Project to Improve Utilization of Sputum Cultures in Hospitalized Patients With Pneumonia P1345 The Cost-effectiveness of the Plasma Microbial Cell-free DNA (mcfDNA) Sequencing Karius Test ® to Establish an Etiology of Pneumonia Amongst Hospitalized Immunocompromised Adult Patients San Diego Convention Center Area L (Hall H, Ground Level)

ATS 2024 Conference Program • San Diego, CA